Genentech Can't Follow Up Rituxan Alone: Arbitrators

Law360, New York (June 17, 2009, 12:00 AM EDT) -- An arbitration panel has ordered Genentech Inc. to stop its work on three follow-up drugs to Rituxan, a popular cancer and arthritis drug it developed through a partnership with Biogen Idec, finding that both companies need to have a say in developing such drugs under their agreement.

The arbitration panel ruled that Genentech can't independently develop drugs for neuromyelitis optica, multiple sclerosis and cancer, but can continue developing drugs for rheumatoid arthritis and lupus, Biogen announced Monday. Biogen initiated the arbitration proceeding in 2006, seeking to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.